Life Sciences Tools and Services

Avantor

Avantor director increases company shares

Avantor released FY2026 Q1 earnings on April 29 Pre-Market (EST), actual revenue USD 1.581 B (forecast USD 1.545 B), actual EPS USD 0.06 (forecast USD 0.0446)

Avantor Reports Q1 Sales Above Estimates

Avantor to Release FY2026 Q1 Earnings on April 29 Pre-Market EST, Forecast Revenue USD 1.543 B, EPS USD 0.0517

Avantor Holds Annual General Meeting in 2026

Avantor Inc. Director Purchases Company Shares

Avantor released FY2025 Q4 earnings on February 11 Pre-Market EST, forecasted revenue USD 1.636 B, forecasted EPS USD 0.1169

Avantor released FY2025 Annual Earnings on February 11 Pre-Market (EST), Actual Revenue: USD 6.552 B (Forecast: USD 6.525 B), Actual EPS: USD -0.78 (Forecast: USD -0.7316)

Avantor Reports Q4 Revenue

Avantor to release FY2025 Q4 earnings on February 11, 2026, pre-market EST; forecast revenue USD 1.636 B, EPS USD 0.1169

Avantor Receives Consensus Hold Rating from Analysts and Insider Buys Shares

Avantor Inc. Unveils Growth Strategy and Operational Improvements at JPM Healthcare Conference

KLP Kapitalforvaltning AS Reduces Stake in Avantor, Inc.

Analysts Downgrade Avantor Stock Ratings

Analysts Cut Target Price Valuation for Avantor Inc.

Avantor Inc CEO Emmanuel Ligner to Attend 44th Annual JPMorgan Healthcare Conference and Speak

Jefferies analyst downgrades Avantor to sell

Avantor Inc. Reports $785 Million Non-Cash Goodwill Impairment Charge

BofA Downgrades Avantor to Neutral

Avantor, Inc. Receives Multiple Hold Ratings From Brokers, Shares Rise

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

AVTR

SBIO

LABU

The global Cell Culture Media Market is projected to grow from USD 3.7 billion in 2026 to USD 7.1 billion by 2036, driven by rising biologics production and expanding cell therapy pipelines. Key growth factors include increased adoption of serum-free formulations and demand for GMP-grade manufacturing. Major suppliers like Avantor and Thermo Fisher are enhancing their production capabilities to meet this demand. Challenges include high raw material costs and regulatory complexities. China is expected to lead growth, with significant expansions in biopharmaceutical manufacturing.

prnewswire

Thermo Fisher Scentific

Proshares Ultra Nasdaq Biotech

ALPS Medical Breakthrough

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

iShares Biotechnology ETF

Lonza

06:39 ETGlobal Cell Culture Media Market Outlook 2026-2036: Biologics Manufacturing and Cell Therapy Expansion Accelerate Growth for Avantor, Thermo Fisher Scientific, and Lonza Group AG

Avantor® Announces Gerard (Jerry) Porreca as Executive Vice President, Quality and Regulatory | AVTR Stock News

StockTitan

Avantor® Announces Gerard (Jerry) Porreca as Executive Vice President, Quality and Regulatory | AVTR Stock News

Comerica Bank has reduced its stake in Avantor, Inc. (NYSE:AVTR) by 30.2%, selling 127,981 shares in the fourth quarter, leaving it with 296,375 shares valued at $3.4 million. Other hedge funds have also adjusted their positions in Avantor. The stock opened at $7.97, with a market cap of $5.44 billion. Analysts have mixed ratings on the stock, with a consensus rating of "Hold" and a price target of $11.39. Recent insider purchases indicate confidence in the company's future performance.

Market Beat

Comerica

Evercore

Stifel Financial

COMERICA INC 6.875 % DEP PFD SER B

STIFEL FINANCIAL CORP 6.125% DEP SHS REP 1/1000 NON CU PF SR C

Stifel Financial Pref Share SFB 5.2 10/15/47

STIFEL FINANCIAL CORP 6.25%NON CUM DEP SHS REP 1/1000TH SER B

STIFEL FINANCIAL CORP 4.50% DEP SHS REP 1/1000TH PREF SHS SR D

Comerica Bank Sells 127,981 Shares of Avantor, Inc. $AVTR

Avantor (AVTR) has reported an increased risk of goodwill impairment for its VWR Distribution unit due to a decline in share price and market capitalization. The unit's fair value is only slightly above its carrying value, making it vulnerable to adverse changes in performance or market conditions. This could lead to a significant non-cash impairment charge, affecting reported earnings and financial metrics. Currently, Wall Street holds a consensus rating of Hold on AVTR stock, with 2 Buys, 2 Sells, and 8 Holds.

Tip Ranks

SPDR S&P Health Equip

iShares US Medical Devices

Avantor’s VWR Unit Faces Heightened Goodwill Impairment Risk Amid Narrow Valuation Cushion

Avantor has been maintained at a Hold rating by analyst Daniel Brennan from TD Cowen, with a price target reduced to $9. The decision reflects a balance of improving company actions and ongoing risks, including execution challenges and competitive pressures. Despite modestly exceeding first-quarter expectations and management's confidence in a second-half recovery, the need for faster growth raises concerns. The VWR distribution and Bioscience & Medtech segments are still facing organic declines, prompting Brennan to await clearer evidence of sustainable growth before reassessing the stock.

Agilent Tech

Illumina

Avantor Kept at Hold as Analyst Trims Price Target to $9 Amid Execution and Market Recovery Risks

Avantor, Inc. (NYSE:AVTR) shares gapped up to $8.50 after reporting better-than-expected quarterly earnings of $0.17 per share, surpassing estimates of $0.16. The company also reported revenue of $1.58 billion, exceeding expectations of $1.55 billion. Analysts have mixed ratings on the stock, with a consensus price target of $11.54. Recent insider purchases indicate confidence in the company, while institutional investors hold 95.08% of the stock. Despite the positive earnings, the stock is down 0.4% with a market cap of $5.34 billion.

Jefferies Financial

Morgan Stanley

Barclays

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

Avantor (NYSE:AVTR) Shares Gap Up  on Strong Earnings

ETSY

Etsy shares are trading higher after the company reported better-than-expected Q1 financial results.

benzinga_article

Avantor (NYSE:AVTR) reported its Q1 2026 earnings, revealing revenue of $1.581 billion, a 4% organic decline. VWR Distribution revenue was $1.15 billion, down 5% organically, though e-commerce showed improvement. The company reaffirmed its full-year guidance, expecting organic growth in the latter half of the year. Leadership changes were made to support a revival strategy, with a focus on operational performance and digital capabilities. Adjusted EPS for the quarter was $0.17, exceeding expectations.

Transcript: Avantor Q1 2026 Earnings Conference Call

Avantor(AVTR.US)

06:39 ETGlobal Cell Culture Media Market Outlook 2026-2036: Biologics Manufacturing and Cell Therapy Expansion Accelerate Growth for Avantor, Thermo Fisher Scientific, and Lonza Group AG

Avantor® Announces Gerard (Jerry) Porreca as Executive Vice President, Quality and Regulatory | AVTR Stock News

Comerica Bank Sells 127,981 Shares of Avantor, Inc. $AVTR

Avantor’s VWR Unit Faces Heightened Goodwill Impairment Risk Amid Narrow Valuation Cushion

Avantor Kept at Hold as Analyst Trims Price Target to $9 Amid Execution and Market Recovery Risks

Avantor (NYSE:AVTR) Shares Gap Up on Strong Earnings

Etsy shares are trading higher after the company reported better-than-expected Q1 financial results.

Transcript: Avantor Q1 2026 Earnings Conference Call